Literature DB >> 28285394

HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis.

Rabia Nawaz1, Sadia Zahid1, Muhammad Idrees2, Shazia Rafique1, Muhammad Shahid1, Ammara Ahad1, Iram Amin1, Iqra Almas1, Samia Afzal3.   

Abstract

Over the course of time, Hepatitis C has become a universal health menace. Its deleterious effects on human liver encompass a lot of physiological, genetic as well as epigenetic alterations. Fatty liver (Hepatic steatosis) is an inflammation having multifactorial ancestries; one of them is HCV (steatohepatitis). HCV boosts several cellular pathways involving up-regulation of a number of cytokines. Current study reviews the regulation of some selective key cytokines during HCV infection, to help generate an improved understanding of their role. These cytokines, IL-1β, IL-6, TNF-α, and IFN-ϒ, are inflammatory markers of the body. These particular markers along with others help hepatocytes against viral infestation. However, recently, their association has been found in degradation of liver on the trail heading to non-alcoholic steatohepatitis (NASH). Consequently, the disturbance in their equilibrium has been repeatedly reported during HCV infection. Quite a number of findings are affirming their up-regulation. Although these cell markers are stimulated by hepatocytes as their standard protection mechanism, but modern studies have testified the paradoxical nature of this defense line. Nevertheless, direct molecular or epigenetic research is needed to question the actual molecular progressions and directions commanding liver to steatosis, cirrhosis, or eventually HCC (Hepatocellular Carcinoma).

Entities:  

Keywords:  Hepatitis C virus (HCV); Interferon (IFN); Interleukins (IL); Non-alcoholic steatohepatitis (NASH); Tumor necrosis factor (TNF)

Mesh:

Substances:

Year:  2017        PMID: 28285394     DOI: 10.1007/s00011-017-1029-3

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  115 in total

1.  Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C.

Authors:  Elena Lima-Cabello; María Victoria García-Mediavilla; María E Miquilena-Colina; Javier Vargas-Castrillón; Tamara Lozano-Rodríguez; Miguel Fernández-Bermejo; José Luis Olcoz; Javier González-Gallego; Carmelo García-Monzón; Sonia Sánchez-Campos
Journal:  Clin Sci (Lond)       Date:  2011-03       Impact factor: 6.124

2.  Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor.

Authors:  Y Yamada; I Kirillova; J J Peschon; N Fausto
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 3.  Biologically active products of stimulated liver macrophages (Kupffer cells).

Authors:  K Decker
Journal:  Eur J Biochem       Date:  1990-09-11

4.  Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease.

Authors:  Zhiping Li; Mark J Soloski; Anna Mae Diehl
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

Review 5.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

6.  Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study.

Authors:  Y S Huang; S J Hwang; C Y Chan; J C Wu; Y Chao; F Y Chang; S D Lee
Journal:  Zhonghua Yi Xue Za Zhi (Taipei)       Date:  1999-06

7.  Metformin reverses fatty liver disease in obese, leptin-deficient mice.

Authors:  H Z Lin; S Q Yang; C Chuckaree; F Kuhajda; G Ronnet; A M Diehl
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

8.  Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.

Authors:  John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust
Journal:  J Hepatol       Date:  2006-03-20       Impact factor: 25.083

9.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

10.  Inflammasome recognition of influenza virus is essential for adaptive immune responses.

Authors:  Takeshi Ichinohe; Heung Kyu Lee; Yasunori Ogura; Richard Flavell; Akiko Iwasaki
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

View more
  6 in total

Review 1.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

2.  Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats.

Authors:  Mohamed A Ibrahim; Asmaa Abdel-Aziz; Azza El-Sheikh; Maha Kamel; Al-Zahraa Khalil; Hisham Abdelhaleem
Journal:  Clin Exp Hepatol       Date:  2018-09-10

3.  Reinfection of Transplanted Livers in HCV- and HCV/HIV-Infected Patients Is Characterized by a Different MicroRNA Expression Profile.

Authors:  Emiliano Dalla; Michela Bulfoni; Daniela Cesselli; Riccardo Pravisani; Masaaki Hidaka; Susumu Eguchi; Umberto Baccarani
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

4.  GVS-12 attenuates non-alcoholic steatohepatitis by suppressing inflammatory responses via PPARγ/STAT3 signaling pathways.

Authors:  Yuhui Wang; Xiyang Zhang; Bo Yuan; Xi Lu; Dongxuan Zheng; Kefeng Zhang; Mingli Zhong; Xiaotian Xu; Xiaoqun Duan
Journal:  RSC Adv       Date:  2019-03-26       Impact factor: 3.361

Review 5.  Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals.

Authors:  Ivan Schietroma; Giuseppe Corano Scheri; Claudia Pinacchio; Maura Statzu; Arnolfo Petruzziello; Vincenzo Vullo
Journal:  Open Virol J       Date:  2018-02-28

6.  Interleukin-6 polymorphisms in HCC patients chronically infected with HCV.

Authors:  Faisal Adnan; Najeeb Ullah Khan; Aqib Iqbal; Ijaz Ali; Arnolfo Petruzziello; Rocco Sabatino; Annunziata Guzzo; Giovanna Loquercio; Gerardo Botti; Sanaullah Khan; Muhammad Naeem; Muhammad Ismail Khan
Journal:  Infect Agent Cancer       Date:  2020-04-01       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.